- Home
- JANX
as 07-26-2024 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $64.63 | AVG Volume (30 days): | 622.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.65 - $65.60 | Next Earning Date: | 08-06-2024 |
| Revenue: | $7,287,000 | Revenue Growth: | -19.67% |
| Revenue Growth (this year): | -53.07% | Revenue Growth (next year): | -26.50% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lichter Jay | JANX | Director10% Owner | Jun 3 '24 | Sell | $54.75 | 691,525 | $37,860,993.75 | 3,340,018 | SEC Form 4 |
| Lichter Jay | JANX | Director10% Owner | Jun 3 '24 | Sell | $54.75 | 131,196 | $7,182,981.00 | 633,673 | SEC Form 4 |
| Lichter Jay | JANX | Director10% Owner | Jun 3 '24 | Sell | $54.75 | 677,279 | $37,081,025.25 | 3,271,216 | SEC Form 4 |
| Reardon Tighe | JANX | Acting Chief Financial Officer | Jun 3 '24 | Sell | $54.75 | 691,525 | $37,860,993.75 | 3,340,018 | SEC Form 4 |
| Reardon Tighe | JANX | Acting Chief Financial Officer | Jun 3 '24 | Sell | $54.75 | 131,196 | $7,182,981.00 | 633,673 | SEC Form 4 |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Jun 3 '24 | Sell | $54.75 | 677,279 | $37,081,025.25 | 3,271,216 | SEC Form 4 |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Jun 3 '24 | Sell | $54.75 | 131,196 | $7,182,981.00 | 633,673 | SEC Form 4 |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Jun 3 '24 | Sell | $54.75 | 691,525 | $37,860,993.75 | 3,340,018 | SEC Form 4 |
| Reardon Tighe | JANX | Acting Chief Financial Officer | Nov 13 '23 | Buy | $5.87 | 849,854 | $4,988,642.98 | 849,854 | SEC Form 4 |
| Lichter Jay | JANX | Director10% Owner | Nov 13 '23 | Buy | $5.87 | 849,854 | $4,988,642.98 | 849,854 | SEC Form 4 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Janux Therapeutics Announces Updates to Board of Directors
Barrons.com
a month ago
TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Simply Wall St.
2 months ago
OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
Barrons.com
2 months ago
Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.